Fundamental leadership · SEC EDGAR · no analyst estimates · as of 2026-07-20
Which industries lead on earnings and sales, today. As of 2026-07-20, 4,463 companies clear the eligibility gates and 1,339 rank Leader or Strong on filed EPS and revenue growth. The strongest industry group is Precious Metals with 29 Leader or Strong names. 19.4% of eligible companies also sit in the top relative-strength quintile — fundamentals and price agreeing.
Theme
| Ticker | Company | Rank | Δ3wk | Verdict | EPS YoY | Sales YoY | Margin Δ | 6M RS | Filed |
|---|---|---|---|---|---|---|---|---|---|
| LQDA | Liquidia Corporation Common StockBiotech & Genomics | 98 | ±0 | Leader33 | to profit↑ | >+999%↑ | >+10,000 bps | 97 | 2026-05-11 |
| BEAM | Beam Therapeutics Inc. Common StockBiotech & Genomics | 97 | ±0 | Leader | loss narrowed 27% | +325%↑ | >+10,000 bps | 34 | 2026-05-07 |
| NBIX | Neurocrine Biosciences IncBiotech & Genomics | 97 | ±0 | Leader | >+999% | +42%↑ | +492 bps | 84 | 2026-05-05 |
| TGTX | TG Therapeutics, Inc.Biotech & Genomics | 97 | ±0 | Leader | +300% | +70%↓ | +586 bps | 95 | 2026-05-06 |
| VCYT | Veracyte, Inc.Biotech & Genomics | 93 | ±0 | Leader | +289% | +21%↑ | +919 bps | 88 | 2026-05-06 |
| ALNY | Alnylam Pharmaceuticals, Inc.Biotech & Genomics | 92 | ±0 | Leader | loss narrowed 73%↑ | +85% | +2137 bps | 28 | 2026-04-30 |
| INCY | Incyte Genomics IncBiotech & Genomics | 88 | ±0 | Strong | +84% | +21% | +2609 bps | 67 | 2026-04-28 |
| URGN | UroGen Pharma Ltd. Ordinary SharesBiotech & Genomics | 88 | ±0 | Strong33 | loss narrowed 49%↑ | +152%↑ | +4049 bps | 97 | 2026-05-06 |
| NTLA | Intellia Therapeutics, IncBiotech & Genomics | 79 | ±0 | Strong | loss narrowed 26% | -9% | >+10,000 bps | 44 | 2026-05-11 |
| EXEL | Exelixis IncBiotech & Genomics | 76 | ±0 | Strong | +44% | +10% | +628 bps | 79 | 2026-05-05 |
| ABCL | AbCellera Biologics Inc. Common SharesBiotech & Genomics | 75 | ±0 | Strong | loss narrowed 7% | +96% | >+10,000 bps | 88 | 2026-05-11 |
| INSM | Insmed, Inc.Biotech & Genomics | 75 | ±0 | Strong33 | loss narrowed 46%↑ | +230%↑ | >+10,000 bps | 22 | 2026-05-07 |
| RYTM | Rhythm Pharmaceuticals, Inc. Common StockBiotech & Genomics | 74 | ±0 | Strong | loss widened 2%↑ | +84% | +3524 bps | 51 | 2026-05-05 |
| QURE | uniQure N.V.Biotech & Genomics | 73 | ±0 | Strong | loss widened 4% | +127% | <-10,000 bps | 96 | 2026-05-05 |
| GH | Guardant Health, Inc. Common StockBiotech & Genomics | 70 | ±0 | Strong | loss widened 10% | +48%↑ | +1735 bps | 85 | 2026-05-07 |
| VRTX | Vertex Pharmaceuticals IncBiotech & Genomics | 69 | ±0 | Strong | +61%↑ | +8%↓ | +4500 bps | 66 | 2026-05-05 |
| TWST | Twist Bioscience Corporation Common StockBiotech & Genomics | 68 | ±0 | Average | loss widened 8%↓ | +19%↑ | +2396 bps | 97 | 2026-05-04 |
| MRNA | Moderna, Inc. Common StockBiotech & Genomics | 63 | ±0 | Average | loss widened 35% | +260%↑ | -3597 bps | 92 | 2026-05-01 |
| TXG | 10x Genomics, Inc. Class A Common StockBiotech & Genomics | 61 | ±0 | Average | loss narrowed 64% | -3% | +2154 bps | 97 | 2026-05-08 |
| RARE | Ultragenyx Pharmaceutical Inc.Biotech & Genomics | 60 | ±0 | Average | loss widened 17% | -2% | +317 bps | 78 | 2026-05-06 |
| IONS | Ionis Pharmaceuticals, Inc. Common StockBiotech & Genomics | 55 | ±0 | Average | loss narrowed 40% | +87% | — | 23 | 2026-04-29 |
| CORT | Corcept Therapeutics Inc.Biotech & Genomics | 34 | ±0 | Average | to loss | +5%↓ | -1724 bps | 98 | 2026-04-30 |
| CRSP | CRISPR Therapeutics AGBiotech & Genomics | 30 | ±0 | Average | loss narrowed 19% | +69% | — | 38 | 2026-05-04 |
| KYMR | Kymera Therapeutics, Inc. Common StockBiotech & Genomics | 24 | ±0 | Laggard | loss narrowed 13%↑ | +55% | <-10,000 bps | 93 | 2026-04-30 |
| PSNL | Personalis, Inc. Common StockBiotech & Genomics | 20 | ±0 | Laggard | loss widened 61%↓ | -25% | -8063 bps | 88 | 2026-05-07 |
| RVMD | Revolution Medicines, Inc. Common StockBiotech & Genomics | 13 | ±0 | Laggard | loss widened 103%↓ | — | — | 90 | 2026-05-06 |
| ORKA | Oruka Therapeutics, Inc. Common StockBiotech & Genomics | 9 | ±0 | Laggard | loss widened 156%↑ | — | — | 98 | 2026-05-13 |
| PRAX | Praxis Precision Medicines, Inc. Common StockBiotech & Genomics | 9 | +1 | Laggard | loss narrowed 3% | -100% | — | 57 | 2026-05-07 |
| SRPT | Sarepta Therapeutics,, Inc. Common StockBiotech & Genomics | 8 | ±0 | Laggard | to profit | -46%↓ | +316 bps | 30 | 2026-05-06 |
| VKTX | Viking Therapeutics, IncGLP-1 / ObesityBiotech & Genomics | 6 | ±0 | Laggard | loss widened 234% | — | — | 71 | 2026-04-30 |
Every US common stock and ADR in the universe is ranked on fundamental growth from the numbers companies actually filed with the SEC — no analyst estimates, no forward projections. TickerStance reads EDGAR XBRL company facts directly.
To qualify, a company must have at least six quarters of EPS and revenue history available and the most-recent filing must be no older than 200 days. That gate keeps the rankings grounded in current operating conditions rather than stale data.
Two growth factors are computed: recent year-over-year growth (latest quarter vs the same quarter last year) blended with a three-year trend score. Both factors are percentile-ranked universe-wide so a rank of 90 means the company grows faster than 90% of its peers, regardless of absolute size. The two factor percentiles are then combined into a single 1-99 fundamentals rank.
Operating margin is tracked as context — a company whose margins are expanding while growing revenue is a stronger story than one shrinking margins to buy growth — but margin level is not a direct rank input. Industries, sectors, and themes inherit their rank from the median of their members, so a strong cluster is one where most constituent companies score well, not just a few outliers.
The RS overlap metric shows what share of a cluster's eligible companies sit in the top relative-strength quintile (6M RS rank ≥ 80). When a fundamentally strong group also carries broad price leadership, it has both the earnings story and the institutional sponsorship — the combination that historically precedes sustained outperformance.
Every US common stock and ADR with sufficient SEC filing history gets a 1-99 fundamentals rank: EPS and revenue growth factors are computed from filed XBRL data, percentile-ranked across the universe, and blended. Ranks of 90+ are Leaders, 70-89 Strong, 30-69 Average, below 30 Laggards. Industries, sectors, and themes are then ranked by their members' median rank.
SEC EDGAR XBRL company facts — the numbers companies actually filed. No analyst estimates, no forward guidance, no third-party data vendor.
Sign-aware: a narrowed loss counts as improvement, a widened loss as deterioration, a swing to profit as a turnaround. Conventional percent math misreads losses (a loss shrinking from -$0.12 to -$0.07 is improvement, not "down 42%"), so the table says "loss narrowed 42%" instead of printing a misleading percentage.
The change in a group's median fundamentals rank versus 15 and 30 trading days ago — the classic "improving group" read. Positive means the group is gaining rank. Dashes mean the history window isn't available yet.
Once per US trading day after the close. The as-of date in the header is the snapshot date.